Navigation Links
Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
Date:6/19/2013

emissions lasting in excess of two years in the great majority of patients treated."  

Study participants were enrolled selected to receive either ibrutinib 420 mg (n=51) or 840 mg (n=34) as a once-daily, oral monotherapy. Both doses were associated with overall response rates of 71 percent. Del17p patients had an overall response rate of 68 percent. Two patients in the 420 mg dose arm had complete responses and 34 patients had partial responses. Across all relapsed or refractory patients, including the high risk patients, the estimated progression-free survival at 26 months was 75 percent. An additional 20 percent of patients treated with the 420 mg dose and 15 percent of patients taking the 840 mg dose achieved a partial response accompanied by lymphocytosis, an elevated blood lymphocyte count.

The majority of adverse events (AEs) observed in the study were considered to be Grade 1 or 2 in severity, including diarrhea, infections and fatigue. A total of six patients taking ibrutinib experienced an AE leading them to discontinue treatment with the drug. Severe AEs observed during the treatment period include pneumonia and dehydration (12 percent and six percent, respectively), as well anemia, neutropenia and thrombocytopenia (six percent, 15 percent and six percent, respectively). Grade 3-4 hematological toxicities were not common.

Data from this study were presented at the annual meeting of the American Society of Hematology in December 2012.

Study Design
The Phase 1b/2, open-label, multicenter study was designed to determine the safety, efficacy, pharmacokinetics and pharmacodynamics of ibrutinib in patients with relapsed or refractory CLL. The primary objective of the study was to determine the safety of the two fixed-dose regimens of ibrutinib, assessed by evaluating the frequency and severity of AEs. Secondary efficacy endpoints included: overall response rate, progression-free survival and an exploratory endpoint of overa
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
5. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
8. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
9. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
10. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
11. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  Daktari Diagnostics today announced ... the United States and Canada ... test. The deal, worth up to $8.5 million over the ... the clinical validation and regulatory approval of Daktari,s HCV test. ... a point-of-care instrument that can detect low levels of virus ...
(Date:8/31/2015)... August 31, 2015 A ... global cardiovascular monitoring and diagnostic devices market stood ... to reach a value of approximately US$7.0 billion ... between 2013 and 2019. The title of the ... (ECG, Holter Monitors, Event Monitors, Cardiovascular Diagnostic Catheters, ...
(Date:8/31/2015)... -- On August 5, 2015, the U.S. District Court for ... motions to dismiss securities class action claims against Galena ... its directors. The class actions allege that the individual ... artificially inflate Galena,s stock price, and during an eighteen ... sold massive amounts of their personally-held shares. ...
Breaking Medicine Technology:Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 2Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches of Fiduciary Duty 2
(Date:8/31/2015)... ... August 31, 2015 , ... CareSource, ... and Corporate Communications. In this capacity, Michael will provide strategic leadership for CareSource’s ... leader in consumer-focused programs that have contributed to the company’s rapid growth. As ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... In an ... from the Plastic and Reconstructive Surgery Global Open Journal that discusses the future of ... article discussed how, in the future, customized implants, prosthetics, and other 3-D printed tools ...
(Date:8/31/2015)... ... , ... NJ Top Docs Presents, Dr. Michael Betsy! Dr. Betsy has been reviewed and ... Michael Betsy graduated from Don Bosco Prep in 1990 and was Class Salutatorian. He ... sports in his senior year. He was inducted into the National Honor Society as ...
(Date:8/31/2015)... CA (PRWEB) , ... August 31, 2015 , ... According ... of the University of Sweden showed that most adolescents who underwent bariatric surgery “felt ... average, the 88 adolescent bariatric patients who participated in the study felt that their ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dad Phil, son Scott, ... on Aug. 26, generously hosted by the Collinsville Chamber of Commerce, but the ... Call Center and website since Aug. 17. , The Greens have operated Green ...
Breaking Medicine News(10 mins):Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Article on Adolescent Bariatric Surgery Demonstrates the Powerful Effect of Being in Control, Notes Dr. Michael Feiz 2Health News:Article on Adolescent Bariatric Surgery Demonstrates the Powerful Effect of Being in Control, Notes Dr. Michael Feiz 3Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2
... those trying to lose weight, there is a lot of confusion ... now is // to eat a low carbohydrate diet, a new ... weight loss -- even when the amount of food is not ... 12-week low fat, high-carb diet alone and in combination with exercise. ...
... have Parkinson’s disease. It is a neurological condition // that ... therapy can improve both of these problems. A pulse of ... movement. This is done inorder to improve stiffness in patients. ... magnetic stimulation. ,For nearly 15 years, Criner has dealt ...
... shows the reason some adolescents experience depression could be ... to have a smaller hippocampus -- the part of ... ,Researchers sampled nearly 30 adolescents between ages 13 ... major depressive disorder.Magnetic resonance imaging was performed to measure ...
... most common type of plastic surgery performed for cosmetic ... 269,000 procedures were performed. ,Researchers examined data from ... the mammogram results of women with breast implants to ... of the study show breast implants decreased the sensitivity ...
... who suffer from migraine headaches may be at risk for ... brain where the tissue has died. ,Researchers studied ... grouped the patients into categories of having migraines with visual ... group was also included in the study. Participants had a ...
... bacterial infection that affects the gums and bones supporting ... can not only reveal the general health of patients ... ,Researchers from Japan studied more than 7,450 men and ... 37 items, including cholesterol and C-reactive protein, which are ...
Cached Medicine News:
... viscoelastic insert runs alongside the Achilles ... and targeted intermittent compression during movement. ... irritation of the Achilles tendon is ... wedge (raises heel about 6 mm). ...
... II is effective for acute, rehabilitation, ... to help prevent injury and reinjury ... exceptional support for medial and lateral ... plantar flexion. Unique split-pad system includes ...
Softsplint after bunion surgery. Hook-and-loop closure. Maintains hallux positioning and metatarsophalangeal alignment. Washable....
... Pediatric Ankle Cryo/Cuff is specifically designed to ... Using a combination of controlled compression and ... pain. The Pediatric Ankle Cryo/Cuff is ideal ... episodes in hemophilia.,The Pediatric Ankle Cryo/Cuff is ...
Medicine Products: